Canetas Emagrecedoras: Entenda a “Agonorexia” e Seus Riscos

The increasing use of so-called “skinny pens” or “weight loss pens” is prompting discussion about the effects associated with GLP-1 agonists. Originally intended for individuals with type 2 diabetes and obesity, these medications are now being used by people without formal clinical indications.

A New Concern: Agonorexia

As the use of these medications expands, healthcare professionals are reporting cases of extreme appetite loss. This phenomenon is informally being referred to as “agonorexia,” though This proves not yet a formally recognized diagnostic classification.

Did You Know? These medications act on regions of the brain related to hunger and satiety, and also slow down gastric emptying.

Potential Health Risks

Agonorexia is characterized by a significant reduction in hunger, which can lead to a substantial decrease in food intake. Experts cite potential risks including significant muscle mass loss, nutritional deficiencies, persistent weakness, a weakened immune system, and metabolic alterations.

Accelerated weight loss, in these cases, may be linked to insufficient energy and nutrient intake. Prolonged restriction increases the possibility of malnutrition and functional impairment.

Expert Insight: The medications in question can also interfere with the brain’s reward system, potentially diminishing cravings for substances like alcohol and tobacco. This highlights the complex neurological effects of these drugs beyond their intended metabolic impact.

Endocrinologist Marina Karam notes that these medications “act in brain regions related to hunger and satiety.” She adds that the drugs can interfere with the reward system, “They decrease the desire to drink, and even to smoke, because they act on the reward system.” Healthcare professionals recommend medical prescription and regular monitoring during treatment.

Frequently Asked Questions

What are GLP-1 agonists?

GLP-1 agonists are medications originally indicated for type 2 diabetes and obesity.

What is “agonorexia”?

Agonorexia is a term used to describe extreme appetite loss observed in some individuals using GLP-1 agonists, though it is not an official medical diagnosis.

What are the potential risks associated with significant appetite loss?

Potential risks include significant muscle mass loss, nutritional deficiencies, persistent weakness, a weakened immune system, and metabolic alterations.

As these medications continue to gain attention, it remains to be seen how widespread the issue of appetite suppression will become, and what long-term effects may emerge from off-label use.